Sibutramine
(Redirected from Reductil)
Introduction[edit | edit source]
Sibutramine is a pharmacological agent that functions as a serotonin and norepinephrine reuptake inhibitor. Originally designed for the treatment of depression, it was later repurposed and used primarily for the short- and long-term management of obesity. However, in 2010, its usage was withdrawn due to an observed increased risk of cardiovascular events.
Mechanism of Action[edit | edit source]
Sibutramine, chemically referred to as si bue' tra meen, belongs to the beta-phenylethylamine class of compounds. It acts by inhibiting the reuptake of two neurotransmitters in the brain: serotonin and norepinephrine. While it was initially developed to act as an antidepressant, sibutramine exhibited a minimal therapeutic effect on depression. However, an unintended consequence of its administration was weight loss, which researchers linked to decreased appetite and a subsequent reduction in caloric intake.
Relationship with Liver Toxicity[edit | edit source]
In comprehensive clinical trials, the administration of sibutramine did not correlate with elevated serum enzyme levels, indicating a low risk of liver-related side effects. However, on rare occasions, sibutramine has been connected to cases of clinically significant acute liver injury.
FDA Approval and Subsequent Withdrawal[edit | edit source]
The FDA granted approval for sibutramine as an obesity treatment in the United States in 1997. The drug enjoyed widespread prescription until 2010 when emerging research studies demonstrated a concerning association between sibutramine usage and an increased likelihood of experiencing myocardial infarction and stroke. In light of these findings, the drug was officially withdrawn from the market.
Conclusion[edit | edit source]
While sibutramine once showed promise as a treatment for obesity, concerns about its safety profile, particularly regarding cardiovascular events, led to its removal from clinical use. Its history underscores the importance of continued post-market surveillance for all approved medications.
| Sibutramine Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen
